NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

190.76B

Vuru Grade

69.64/100

Current Price

$80.11
-0.03 (-0.04%)

Growth Price

$56.04
Overvalued by 30.04%

Stability Price

$14.58
Overvalued by 81.80%

Company Metrics

  • P/E 28.57
  • P/S 3.82
  • P/B 2.66
  • EPS 2.80
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.72 / 3.39 %
  • Avg. Vol. 2.25M
  • Shares 2.38B
  • Market Cap. 190.76B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Can Novartis AG (ADR) Reach Financial Stability via Restructuring?
Business Finance News - May 20, 2016
As Novartis AG (ADR) (NYSE:NVS) head of pharmaceuticals, David Epstein, announced his departure from the company, it initiated the process of restructuring the business portfolios.
Can Novartis' Entresto be the New Blockbuster?
Business Finance News - May 23, 2016
Novartis AG (NYSE:NVS) announced that its cardiology drug Entresto (sacubitril/valsartan) has finally got an approval under the new guidelines for the management of heart failure and its allied ailments.
Novartis, Amgen to See Higher Sales of New Heart Drugs - Bidness ETC
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Market Exclusive - Mar 25, 2016
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Novartis AG (ADR) First-Quarter Earnings: What to Expect?
Bidness ETC - Apr 20, 2016
Novartis AG (ADR) (NYSE:NVS) is set to announce its financial results for the first quarter of 2016 (1Q) on Thursday, April 21.
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Business Finance News - Nov 23, 2015
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Novartis AG (ADR) And Roche May Have To Wait Longer For “Outcome-Based ...
Business Finance News - Nov 13, 2015
The outcome-based drug pricing model is becoming a dream for Novartis AG (ADR) (NYSE:NVS) and Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY).
Novartis AG (ADR) Gaps Up; Strong Momentum for Buyers
Franklin Independent - May 22, 2016
The stock of Novartis AG (ADR) (NYSE:NVS) gapped up by $0.35 today and has $118.23 target or 56.00% above today's $75.79 share price.
Novartis AG (ADR) On Collision Course With Amgen, Inc. Again With Another ...
Bidness ETC - Oct 2, 2015
Novartis AG ADR (NYSE:NVS) and Amgen Inc. (NASDAQ:AMGN) seem to be on a collision course again as Novartis is on track to get another biosimilar candidate approved by the US Food and Drug Administration (FDA).
Novartis AG (ADR) Under Pressure on Q1 Revenue Decline
Bidness ETC - Apr 21, 2016
Novartis AG (ADR) (NYSE:NVS) has reported financial results for the first quarter of fiscal year 2016 (1QFY16) with a decline in both, its earnings and revenues.
Novartis (NVS) Misses On Earnings & Sales in Q1 - Nasdaq
Novartis (NVS) Q1 Earnings Miss; Gleevec Hit by Generics - Zacks.com
Novartis AG (ADR) Plunges on Profit Miss
Bidness ETC - Jan 27, 2016
Novartis AG (ADR) (NYSE:NVS) reported lower-than-expected fourth quarter and full year earnings data for fiscal 2015 today, driven mostly by its struggling eye-care business and strengthened dollar.
Novartis and the 'T' Word - Bloomberg
Novartis (NVS) Posts Lower-Than-Expected Earnings in Q4 - Nasdaq